A review published in EXO - Beyond the Cell argues that measuring genes in bulk brain tissue misses much of what matters in neurodegenerative disease. The brain is a patchwork of highly diverse cell populations arranged into anatomical and microenvironmental niches, and averaging molecular signals across a whole tissue sample blurs exactly the differences researchers most want to see. The review, titled "Single-Cell and Spatial Multi-omics for Mapping the Brain Across Molecular Layers," was led by scientists at the University of Campinas (UNICAMP) and the Federal University of Sao Paulo, with collaborating institutions in Brazil.
The authors survey techniques that read several molecular layers at once - transcriptomics, epigenomics, proteomics, metabolomics and spatial profiling - while keeping track of which cell, or which spot in the tissue, each signal came from. That combination is the point. Single-cell multi-omics can expose regulatory relationships that transcriptomic data alone cannot resolve, meaning researchers can start to see not just which genes are switched on but what is doing the switching.
For Alzheimer's specifically, the review points to studies that paired epigenomic and transcriptomic analyses and connected changes in chromatin organization - how DNA is packaged and made accessible - to neuronal vulnerability and disease progression. That is a meaningful shift in framing: rather than treating neuron loss as a uniform process, these methods help explain why particular neurons in particular regions fail first. Similar approaches in Parkinson's disease and psychiatric disorders have identified changes specific to cell types and brain regions, involving neurons, microglia and oligodendrocytes.
The practical value of this work is mostly upstream of the clinic. Identifying which cell populations are most vulnerable, and which regulatory changes precede their decline, gives drug developers more precise targets and gives researchers better candidates for markers of early disease. This is a review of the field rather than new experimental data, so it maps where the tools now stand and what they have already revealed, not a finished picture of Alzheimer's biology.